Biocon Biologics gets USFDA nod for diabetes medication
New Delhi: Biocon Biologics on Wednesday said it has received approval from the US health regulator to market a diabetes treatment medication.
The company, a unit of Biocon Ltd, has received approval from the US Food and Drug Administration (USFDA) for Kirsty as the first and only interchangeable biosimilar to NovoLog (Insulin Aspart).
Kirsty is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. The medication will be available as a single-patient-use prefilled pen for subcutaneous use and a multiple-dose vial for subcutaneous and intravenous use, Biocon said in a statement.
The approval expands Biocon Biologics' biosimilar insulin portfolio, which also includes the interchangeable biosimilar, Semglee (Insulin Glargine-yfgn Injection).
An interchangeable product (IP) is a biological product that is approved based on data demonstrating that it is highly similar to an FDA-approved reference product (RP). Kirsty has been available in Europe and Canada since 2022. As per the company, there are 38.4 million people with diabetes in the US, around 11.6 per cent of the total population, with nearly a quarter of them being undiagnosed. An additional 97.6 million Americans have been identified as prediabetic, it added. According to IQVIA, sales of Insulin Aspart in the US stood around USD 1.9 billion in 2024.
Shares of Biocon were trading 1.44 per cent up at Rs 395.80 apiece on the BSE.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
2 days ago
- Economic Times
Biocon Biologics gets USFDA nod for diabetes medication
Agencies Representative image. New Delhi: Biocon Biologics on Wednesday said it has received approval from the US health regulator to market a diabetes treatment medication. The company, a unit of Biocon Ltd, has received approval from the US Food and Drug Administration (USFDA) for Kirsty as the first and only interchangeable biosimilar to NovoLog (Insulin Aspart). Kirsty is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. The medication will be available as a single-patient-use prefilled pen for subcutaneous use and a multiple-dose vial for subcutaneous and intravenous use, Biocon said in a statement. The approval expands Biocon Biologics' biosimilar insulin portfolio, which also includes the interchangeable biosimilar, Semglee (Insulin Glargine-yfgn Injection). An interchangeable product (IP) is a biological product that is approved based on data demonstrating that it is highly similar to an FDA-approved reference product (RP). Kirsty has been available in Europe and Canada since 2022. As per the company, there are 38.4 million people with diabetes in the US, around 11.6 per cent of the total population, with nearly a quarter of them being undiagnosed. An additional 97.6 million Americans have been identified as prediabetic, it added. According to IQVIA, sales of Insulin Aspart in the US stood around USD 1.9 billion in 2024. Shares of Biocon were trading 1.44 per cent up at Rs 395.80 apiece on the BSE.
New Indian Express
7 days ago
- New Indian Express
Rotary to organise CPR camps, health checkups for frontline cops
BENGALURU: The June 4 stampede at Chinnaswamy Stadium that claimed 11 lives and left several police personnel injured, has shaken up Karnataka. There is a call by senior officers and civic leaders to train police and citizens in the skill of cardiopulmonary resuscitation (CPR). Throwing light on the toll law enforcement officers paid during the stampede, ADGP KV Sharath Chandra said, 'Our men and women in uniform need to be trained not just in riot control but in reviving a life. CPR is useful for both police and people.' Now, with heart attacks increasing among people in their 20s and 30s, CPR literacy has become essential. Rotary Bangalore Northwest has pledged to organize CPR training and health checkups for frontline police, especially armed and civil forces deployed on high-stress bandobast duty. Former police commissioner Bhaskar Rao, advising the public to step up during medical emergencies, said, 'Every second counts. You don't need a uniform to save a life, just training and courage.' Lakshmi Achuta, president of Rotary Bangalore Northwest and Principal Strategic Adviser, Biotech, at Biocon, said it is not enough to train only the police. 'Imagine how many lives could have been saved at the KSCA stampede if more people in the crowd knew CPR. It is about empowering everyone with a life-saving skill.' The movement has also gone global. Rajiv Thalla, based in the United States, has turned a personal heartbreak into a mission. After losing his 23-year-old son Rohan Rajiv to a sudden heart attack, he has taken it on himself to hold free CPR demonstrations, to ensure others don't suffer the same fate. He travels across cities, from Los Angeles to Lucknow, distributing educational material, and partnering with Rotary. His younger son, a doctor, stands by him. 'This isn't just about first aid, but first response. A few minutes can mean the difference between life and death. CPR gives you those minutes.'
Time of India
23-07-2025
- Time of India
Syngene International reports 11% revenue growth and 59% net profit surge in Q1
Synopsis Syngene International, a Biocon subsidiary, reveals an 11% revenue increase to Rs 875 crore for the first quarter. Net profit jumps 59% to Rs 87 crore. Growth is attributed to research services and biologics manufacturing. Operations commenced at Unit III in Bengaluru. Preparations advance for the Bayview facility in the US.
